Kevin Kelly, Founder & CEO, Kelly Intelligence, discusses the Kelly CRISPR & Gene Editing Technology ETF (Nasdaq: XDNA) and the upcoming catalysts in the gene editing revolution that the ETF capitalizes on.
CRISPR technology is on the precipice of changing the world of healthcare as we know it. This technology has the potential to offer a solution to previously unsolvable problems in the healthcare industry, from curing genetic diseases to treating cancers and HIV.
The Kelly CRISPR & Gene Editing Technology ETF (Nasdaq: XDNA) is designed to capitalize on this shift into a new generation of healthcare. Investing in over 20 companies leading the CRISPR revolution, the ETF combines exposure to innovation with high growth potential to provide investors with cost-effective, targeted exposure to the companies leading this revolution in healthcare.
To learn more, register and watch: CRISPR & Gene Editing Revolution – Upcoming Catalysts (XDNA ETF)
Topics include:
- What is CRISPR & Gene Editing Technology
- 2nd Half Catalysts and developments in 2022
- The Future of Gene Editing
- The Publicly Traded Companies
- The CRISPR & Gene Editing Sub-Sectors: CRISPR & Gene Editing Technology, Gene Editing Development Solutions, Gene Editing Sequencing Solutions
- How to Implement the Kelly CRISPR & Gene Editing Technology ETF (Nasdaq: XDNA)
Kelly Intelligence is an SEC registered investment advisor that seeks to offer investors highly liquid exposure to companies identified as best-in-class among their theme or sector. Kevin Kelly, founder and CEO, is a recognized leader in ETF design and owner of extensive track record launching multi-billion dollar ETFs.